Twelve research firms gave Nashville, Tenn.-based AmSurg shares a "buy" rating, according to The Cerbat Gem.
Here are three quick notes:
1. Firms covering the shares have a one-year price target of $87.88.
2. On Dec. 1, 2016, Robert Baird rated the shares a "buy."
3. During the second quarter last year, LS Investment Advisors increased its position in AmSurg by 68.7 percent.